Ramagopalan SV, Ryan ML. Most-Favored-Nation pricing meets Joint Clinical Assessment: early evidence of compounding pressure on European drug launches. J […]
Cross S, Claxton K, Hill A. Health costs of the UK-US trade deal on pharmaceuticals. BMJ. 2026;394:e340588. Geopolítica: un
Kirson NY, Dooley JM, Ge Z, Chandra A. Taking stock of most-favored nation deals: how have markets reacted? Health Aff
Shiff J, Sutton A. Outcome-Aligned Payments for Technology-Enabled Care-A New CMS Approach to Paying for Chronic Disease Care in Medicare.
Wang Y, Yan X, Li H. A systematic review of the willingness-to-accept and willingness-to-pay disparities in empirical studies in the
Esteban-Fabró R, Coma E, Hermosilla E, et al. Information provision and financial incentives in Catalonia’s public primary care (2010-2019): an
Diaz A, Mead M, Rohde S, et al. Hospitals acquired by private equity firms: increased postoperative mortality for common inpatient
Vallejo-Torres L, Oliva-Moreno J, Lobo F. Exploring the uptake of economic evaluation in Spanish reports positioning medicines for public reimbursement.
Pinilla J, López-Valcárcel BG, Bernal-Delgado E. Unravelling risk selection in Spanish general government employee mutual funds: evidence from cancer hospitalizations
Schoenfeld AJ, Holly KE, Cirillo MN, et al. Surgical Low-Value Care Between Fee-For-Service and Salaried Health Care Systems. JAMA Netw
